Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline microRNA-based signatures predict toxicity and response to anti-CTLA-4 therapy

28 Jul 2025

Abstract excerpt

BACKGROUND: Germline microRNA-based variants (mirSNPs) have been shown to be predictive biomarkers of toxicity and tumor response across cancer treatments, including to anti-PD1/PDL1 immune checkpoint therapy. CTLA-4 inhibitors are another immune checkpoint inhibitor with known significant toxicity in the form of immune related adverse events (irAEs). The potential of mirSNPs to predict irAEs and/or response to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40721801
DOI: 10.1186/s12967-025-06842-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline microRNA-based signatures predict toxicity and response to anti-CTLA-4 therapyPMID 40721801Read ↗

Single-Nucleotide Polymorphisms (SNPs) Can Predict the Efficacy and Toxicity of Cancer Immunotherapy? A Systematic ReviewSemantic proximity Read ↗

Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaSemantic proximity Read ↗

Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approachSemantic proximity Read ↗

Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanoma.Semantic proximity Read ↗

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.Semantic proximity Read ↗

Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type.Semantic proximity Read ↗

Germline genetic variation and predicting immune checkpoint inhibitor induced toxicitySemantic proximity Read ↗

From Genes to Personalized Cancer Care: A Systematic Review of Toxicity-Associated Genetic Variants in Solid Tumor TreatmentsSemantic proximity Read ↗

Whole exome precision oncology targeting synthetic lethal vulnerabilities across the tumor transcriptomeSemantic proximity Read ↗

Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitorsSemantic proximity Read ↗

Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.